Cargando…

Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy

Programmed death protein 1 (PD-1) interaction with PD-L1 deliver immunosuppressive environment for tumor growth, and its blockade with directed monoclonal antibodies (anti-PD-1/anti-PD-L1) has shown remarkable clinical outcome. Lately, their soluble counterparts, sPD-1 and sPD-L1, have been detected...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khan, Muhammad, Zhao, Zhihong, Arooj, Sumbal, Fu, Yuxiang, Liao, Guixiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710690/ https://www.ncbi.nlm.nih.gov/pubmed/33329567 http://dx.doi.org/10.3389/fimmu.2020.587460

Ejemplares similares

Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy
por: Khan, Muhammad, et al.
Publicado: (2021)

Impact of Tyrosine Kinase Inhibitors (TKIs) Combined With Radiation Therapy for the Management of Brain Metastases From Renal Cell Carcinoma
por: Khan, Muhammad, et al.
Publicado: (2020)

Bevacizumab for radiation necrosis following radiotherapy of brain metastatic disease: a systematic review & meta-analysis
por: Khan, Muhammad, et al.
Publicado: (2021)

Lapatinib Plus Local Radiation Therapy for Brain Metastases From HER-2 Positive Breast Cancer Patients and Role of Trastuzumab: A Systematic Review and Meta-Analysis
por: Khan, Muhammad, et al.
Publicado: (2020)

Efficacy of BRAF Inhibitors in Combination With Stereotactic Radiosurgery for the Treatment of Melanoma Brain Metastases: A Systematic Review and Meta-Analysis
por: Khan, Muhammad, et al.
Publicado: (2021)

Bevacizumab Treatment of Radiation-Induced Brain Necrosis: A Systematic Review
por: Liao, Guixiang, et al.
Publicado: (2021)

Radiation Plus Anti-PD-1 Therapy for NSCLC Brain Metastases: A Retrospective Study
por: Liao, Guixiang, et al.
Publicado: (2021)

NK Cell-Based Immune Checkpoint Inhibition
por: Khan, Muhammad, et al.
Publicado: (2020)

Impact of Previous Local Treatment for Brain Metastases on Response to Molecular Targeted Therapy in BRAF-Mutant Melanoma Brain Metastasis: A Systematic Review and Meta-Analysis
por: Liao, Guixiang, et al.
Publicado: (2022)

HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma
por: Huang, Fu-xue, et al.
Publicado: (2022)

Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer
por: Jiang, Siqing, et al.
Publicado: (2022)

Anti-PD1 Therapy Plus Whole-Brain Radiation Therapy May Prolong PFS in Selected Non–Small Cell Lung Cancer Patients with Brain Metastases: A Retrospective Study
por: Khan, Muhammad, et al.
Publicado: (2021)

LRRC3B and its promoter hypomethylation status predicts response to anti-PD-1 based immunotherapy
por: Luo, Linfeng, et al.
Publicado: (2023)

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
por: Niu, Mengke, et al.
Publicado: (2022)

The predictive role of soluble programmed death ligand 1 in digestive system cancers
por: Ruan, Jian, et al.
Publicado: (2023)

Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint
por: Gu, Tingxuan, et al.
Publicado: (2023)

Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study
por: Li, Shuqun, et al.
Publicado: (2023)

A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma
por: Guo, Weinan, et al.
Publicado: (2020)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer
por: Zhu, Xinxin, et al.
Publicado: (2017)

Prognostic value of fatty acid metabolism-related genes in colorectal cancer and their potential implications for immunotherapy
por: Huang, Xi, et al.
Publicado: (2023)

Case Report: Therapeutic Response to Chemo-Immunotherapy in an Advanced Large Cell Lung Carcinoma Patient With Low Values of Multiple Predictive Biomarkers
por: Wang, Guihua, et al.
Publicado: (2021)

Potential Value of miR-221/222 as Diagnostic, Prognostic, and Therapeutic Biomarkers for Diseases
por: Song, Jialin, et al.
Publicado: (2017)

Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy
por: Honrubia-Peris, Beatriz, et al.
Publicado: (2021)

Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy
por: Yao, Han, et al.
Publicado: (2018)

The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment
por: Hudson, Katie, et al.
Publicado: (2020)

Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy
por: Xu, Yanxin, et al.
Publicado: (2022)

Smoking Is Associated With Low Levels of Soluble PD-L1 in Rheumatoid Arthritis
por: Wasén, Caroline, et al.
Publicado: (2018)

Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy
por: Liu, Hao, et al.
Publicado: (2022)

Prognostic value of hematologic parameters in advanced non-small cell lung cancer patients receiving anti-PD-1 inhibitors
por: Zhao, Xinmin, et al.
Publicado: (2022)

Prognostic Value of Carbonic Anhydrase IX Immunohistochemical Expression in Renal Cell Carcinoma: A Meta-Analysis of the Literature
por: Zhao, Zhihong, et al.
Publicado: (2014)

Artificial Intelligence-Assisted Score Analysis for Predicting the Expression of the Immunotherapy Biomarker PD-L1 in Lung Cancer
por: Cheng, Guoping, et al.
Publicado: (2022)

Anti–PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection–Related Advanced Hepatocellular Carcinoma: A Literature Review
por: Li, Bin, et al.
Publicado: (2020)

Immune-related gene-based prognostic index for predicting survival and immunotherapy outcomes in colorectal carcinoma
por: Liang, Zhongqing, et al.
Publicado: (2022)

Prognostic Role of Soluble Programmed Death Ligand 1 in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Liao, Guixiang, et al.
Publicado: (2021)

The Prognostic and Therapeutic Value of PD-L1 in Glioma
por: Chen, Ruo Qiao, et al.
Publicado: (2019)

Exercise sensitizes PD-1/PD-L1 immunotherapy as a hypoxia modulator in the tumor microenvironment of melanoma
por: Yan, Huiyu, et al.
Publicado: (2023)

Editorial: Immunotherapy and small molecule inhibitors as combinational cancer therapeutics
por: Khan, Mohd Wajid Ali, et al.
Publicado: (2023)

Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis
por: Li, Jing-Hua, et al.
Publicado: (2018)

PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer
por: Zhang, Yingzi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l6g6jrkd136rm27b7uqgt75v25